Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pentavalent meningococcal conjugate vaccine A C Y W 135 X - PATH/Serum Institute of India

Next Previous
Drug Profile

Pentavalent meningococcal conjugate vaccine A C Y W 135 X - PATH/Serum Institute of India

Alternative Names: MenACYWX; MenFive; Meningococcal vaccine groups A,C,W-135, Y, X conjugate - PATH; Meningococcal-ACYWX-conjugate-vaccine; NmCV-5; Pentavalent-meningococcal-conjugate-vaccine-A-C-Y-W-135-X; Polyvalent meningitis vaccine - PATH; SIIPL Meningococcal ACYWX Conjugate Vaccine; Thermostable pentavalent conjugate meningococcal vaccine - PATH

Latest Information Update: 06 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PATH; Serum Institute of India
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Meningococcal infections

Most Recent Events

  • 06 Jan 2025 No development reported - Phase-II/III for Meningococcal infections (In the elderly, Prevention, In adults) in India (IM)
  • 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
  • 12 Jul 2023 Pentavalent meningococcal conjugate vaccine A C Y W 135 X achieves World Health Organization (WHO) prequalification for Meningococcal infections (Prevention) in Africa

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top